BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24380501)

  • 21. Human Papillomavirus Vaccination and Pap Smear Uptake Among Young Women in the United States: Role of Provider and Patient.
    Guo F; Hirth JM; Berenson AB
    J Womens Health (Larchmt); 2017 Oct; 26(10):1114-1122. PubMed ID: 28841084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mailed Human Papillomavirus Self-Collection With Papanicolaou Test Referral for Infrequently Screened Women in the United States.
    Smith JS; Des Marais AC; Deal AM; Richman AR; Perez-Heydrich C; Yen-Lieberman B; Barclay L; Belinson J; Rinas A; Brewer NT
    Sex Transm Dis; 2018 Jan; 45(1):42-48. PubMed ID: 28876298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent changes in cervical cancer screening guidelines: U.S. women's willingness for HPV testing instead of Pap testing.
    Thompson EL; Galvin AM; Daley EM; Tatar O; Zimet GD; Rosberger Z
    Prev Med; 2020 Jan; 130():105928. PubMed ID: 31756351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study points to value of HPV screening for cervical cancer: test may be viable alternative to Pap test.
    Printz C
    Cancer; 2014 Dec; 120(23):3589-90. PubMed ID: 25410486
    [No Abstract]   [Full Text] [Related]  

  • 25. Ovarian Cancer Knowledge in Women and Providers Following Education with Inside Knowledge Campaign Materials.
    Puckett MC; Townsend JS; Gelb CA; Hager P; Conlon A; Stewart SL
    J Cancer Educ; 2018 Dec; 33(6):1285-1293. PubMed ID: 28646458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient knowledge and beliefs as barriers to extending cervical cancer screening intervals in Federally Qualified Health Centers.
    Hawkins NA; Benard VB; Greek A; Roland KB; Manninen D; Saraiya M
    Prev Med; 2013 Nov; 57(5):641-5. PubMed ID: 24012831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent Disparities in Cervical Cancer Screening Uptake: Knowledge and Sociodemographic Determinants of Papanicolaou and Human Papillomavirus Testing Among Women in the United States.
    Johnson NL; Head KJ; Scott SF; Zimet GD
    Public Health Rep; 2020; 135(4):483-491. PubMed ID: 32516053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dominican Provider Attitudes Towards HPV Testing for Cervical Cancer Screening and, Current Challenges to Cervical Cancer Prevention in the Dominican Republic: a Mixed Methods Study.
    Liebermann E; Van Devanter N; Frías Gúzman N; Hammer MJ; Ompad D
    J Cancer Educ; 2021 Dec; 36(6):1170-1185. PubMed ID: 32307667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perspectives from health-care providers and women about completing human papillomavirus (HPV) self-testing at home.
    Katz ML; Zimmermann BJ; Moore D; Paskett ED; Reiter PL
    Women Health; 2017; 57(10):1161-1177. PubMed ID: 27700693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
    J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing national cervical cancer screening guidelines: Results from an HIV testing clinic also screening for cervical cancer and HPV in Soweto, South Africa.
    Hopkins KL; Jaffer M; Hlongwane KE; Otwombe K; Dietrich J; Cheyip M; Olivier J; Doherty T; Gray GE
    PLoS One; 2021; 16(7):e0255124. PubMed ID: 34329334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.
    Silver MI; Rositch AF; Phelan-Emrick DF; Gravitt PE
    Cancer Causes Control; 2018 Jan; 29(1):43-50. PubMed ID: 29124542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study.
    Flores Y; Shah K; Lazcano E; Hernández M; Bishai D; Ferris DG; Lörincz A; Hernández P; Salmerón J;
    Salud Publica Mex; 2002; 44(4):335-44. PubMed ID: 12216521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
    Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
    Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.
    Gyllensten U; Sanner K; Gustavsson I; Lindell M; Wikström I; Wilander E
    Br J Cancer; 2011 Aug; 105(5):694-7. PubMed ID: 21811250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human papillomavirus testing in cervical cancer screening.
    Castle PE; Cremer M
    Obstet Gynecol Clin North Am; 2013 Jun; 40(2):377-90. PubMed ID: 23732037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cervical Cancer Screening Preferences Among Trans-Masculine Individuals: Patient-Collected Human Papillomavirus Vaginal Swabs Versus Provider-Administered Pap Tests.
    McDowell M; Pardee DJ; Peitzmeier S; Reisner SL; Agénor M; Alizaga N; Bernstein I; Potter J
    LGBT Health; 2017 Aug; 4(4):252-259. PubMed ID: 28665783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.
    Gage JC; Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Behrens C; Sharma A; Zhao FH; Cuzick J; Yang ZH; Kinney WK
    Cancer Cytopathol; 2014 Nov; 122(11):842-50. PubMed ID: 25045058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.